Portal de Periódicos da CAPES

Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies

2022; Springer Science+Business Media; Volume: 42; Issue: 6 Linguagem: Inglês

10.1007/s10875-022-01252-2

1573-2592

Bengisu Akbil, Tim Meyer, Paula Stubbemann, Charlotte Thibeault, Olga Staudacher, Daniela Niemeyer, Jenny Jansen, Barbara Mühlemann, Jan M. Doehn, Christoph Tabeling, Christian Nußhag, Cédric Hirzel, David Sökler Sanchez, Alexandra Nieters, Achim Lother, Daniel Duerschmied, Nils Schallner, Jan Nikolaus Lieberum, Dietrich August, Siegbert Rieg, Valeria Falcone, Hartmut Hengel, Uwe Kölsch, Nadine Unterwalder, Ralf‐Harto Hübner, Terry C. Jones, Norbert Suttorp, Christian Drosten, Klaus Warnatz, Thibaud Spinetti, Joerg C. Schefold, Thomas Dörner, Leif Erik Sander, Victor M. Corman, Uta Merle, Florian Kurth, Horst von Bernuth, Christian Meisel, Christine Goffinet,

Long-Term Effects of COVID-19

Six to 19% of critically ill COVID-19 patients display circulating auto-antibodies against type I interferons (IFN-AABs). Here, we establish a clinically applicable strategy for early identification of IFN-AAB-positive patients for potential subsequent clinical interventions.